Pancreatic Resectability in Cancers with Known Limited Extension (PRICKLE) A single-centre phase 2a study of Gemcitabine plus Nab-paclitaxel for borderline unresectable locally advanced pancreatic cancer

Trial Profile

Pancreatic Resectability in Cancers with Known Limited Extension (PRICKLE) A single-centre phase 2a study of Gemcitabine plus Nab-paclitaxel for borderline unresectable locally advanced pancreatic cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms PRICKLE
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 Sep 2018.
    • 26 Jul 2017 Status changed from recruiting to discontinued.
    • 23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top